Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1587-1597

  Hassanein, Mohamed ^a   Qian, Jun ^a   Hoeksema, Megan D ^a   Wang, Jing ^b   Jacobovitz, Marie ^a   Ji, Xiangming ^a   Harris, Fredrick T ^a,c   Harris, Bradford K ^a   Boyd, Kelli L ^d   Chen, Heidi ^d   Eisenberg, Rosana ^d   Massion, Pierre P ^a,e  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c MEHARRY MEDICAL COLLEGE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e Veterans Affairs   (United States)

Author keywords

biomarker; glutamine transporters; lung cancer

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEINS AND BINDING PROTEINS; GLUTAMINE; MESSENGER RNA; SOLUTE CARRIER FAMILY A1 MEMBER 5; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; SLC1A5 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CANCER SURVIVAL; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; SLC1A5 GENE; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING; GENE SILENCING; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM ASC; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; GLUTAMINE; HUMANS; LUNG NEOPLASMS; MICE; MOLECULAR TARGETED THERAPY; PROGNOSIS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943399154     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29535     Document Type: Article

References (31)

1. Siegel R, DeSantis C, Virgo K, et al., Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
2. Rivera S, Azcon-Bieto J, Lopez-Soriano FJ, et al., Amino acid metabolism in tumour-bearing mice. Biochem J 1988; 249: 443-9.
3. Huber KR, Mayer EP, Mitchell DF, et al., Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines. Br J Cancer 1987; 55: 653-6.
4. Brower M, Carney DN, Oie HK, et al., Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res 1986; 46: 798-806.
5. Metallo CM, Gameiro PA, Bell EL, et al., Reductive glutamine metabolism by idh1 mediates lipogenesis under hypoxia. Nature 2012; 481: 380-4.
6. Gaglio D, Metallo CM, Gameiro PA, et al., Oncogenic K-ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011; 7: 523.
7. Strohecker AM, Guo JY, Karsli-Uzunbas G, et al., Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 2013; 3: 1272-85.
8. Kikuchi T, Hassanein M, Amann JM, et al., In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers. Mol Cell Proteomics 2012; 11: 916-32.
9. Hassanein M, Hoeksema MD, Shiota M, et al., slc1a5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res 2013; 19: 560-70.
10. Nicklin P, Bergman P, Zhang B, et al., Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-34.
11. Ovejera AA, Houchens DP, Catane R, et al., Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res 1979; 39: 3220-4.
12. Ahluwalia GS, Grem JL, Hao Z, et al., Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther 1990; 46: 243-71.
13. Hensley CT, Wasti AT, DeBerardinis RJ,. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013; 123: 3678-84.
14. Qian J, Zou Y, Rahman JS, et al., Synergy between phosphatidylinositol 3-kinase/akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 2009; 8: 101-9.
15. Massion PP, Kuo WL, Stokoe D, et al., Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002; 62: 3636-40.
16. Gyorffy B, Surowiak P, Budczies J, et al., Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 2013; 8: e82241.
17. Reeve JG, Xiong J, Morgan J, et al., Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 1996; 73: 1193-200.
18. Lorenzo HK, Susin SA,. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Updates 2007; 10: 235-55.
19. Guo B, Godzik A, Reed JC,. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem 2001; 276: 2780-5.
20. Oliver L, Vallette FM,. The role of caspases in cell death and differentiation. Drug Resist Updates 2005; 8: 163-70.
21. Brace JL, Vanderweele DJ, Rudin CM,. Svf1 inhibits reactive oxygen species generation and promotes survival under conditions of oxidative stress in Saccharomyces cerevisiae. Yeast 2005; 22: 641-52.
22. Sayin VI, Ibrahim MX, Larsson E, et al., Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 2014; 6: 221ra15.
23. Son J, Lyssiotis CA, Ying H, et al., Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496: 101-5.
24. Timmerman LA, Holton T, Yuneva M, et al., Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013; 24: 450-65.
25. Fuchs BC, Perez JC, Suetterlin JE, et al., Inducible antisense RNA targeting amino acid transporter atb0/asct2 elicits apoptosis in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2004; 286: g467-g478.
26. Kim CS, Cho SH, Chun HS, et al., BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 2008; 31: 1096-100.
27. Guo JY, Karsli-Uzunbas G, Mathew R, et al., Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013; 27: 1447-61.
28. Cardaci S, Rizza S, Filomeni G, et al., Glutamine deprivation enhances antitumor activity of 3-bromopyruvate through the stabilization of monocarboxylate transporter-1. Cancer Res 2012; 72: 4526-36.
29. Lieberman BP, Ploessl K, Wang L, et al., PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med 2011; 52: 1947-55.
30. Krasikova RN, Kuznetsova OF, Fedorova OS, et al., 4-[18F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization. J Med Chem 2011; 54: 406-10.
31. Ploessl K, Wang L, Lieberman BP, et al., Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents. J Nucl Med 2012; 53: 1616-24.